Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AMY109 in healthy volunteers and patients with endometriosis
jRCT2080223785Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, randomised, double-blind trial in endometriosis comparing AMY109 with Placebo (2 arms). Primary endpoints: Safety, Tolerability and 1 more. Started Jan 2018; status: completed.
02
Drugs
anti-IL-8 monoclonal antibody
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCT2080223785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223785.